Bounce Mobile Systems Inc. (BNCM) and Delex Healthcare Group, Inc. (DELEX), a profitable and fast-growing healthcare and pharmaceutical company, today announce their expansion plans designed to solidify the market position and drive the future growth of DELEX.
With DELEXs successful union and strategic merger alliance with Bounce Mobile Systems Inc. (BNCM), the shared objective of fostering a better market presence, while continuing to meet the gaps of critical care patients with accessible medical treatments, presents an enticing opportunity for interested investors, shareholders, and partners seeking opportunities in the growing Southeast Asia healthcare industry.
With 15 years of business operations, the company, guided by remarkable leaders with extensive experience, managerial and entrepreneurial skills, and knowledge in the pharmaceutical and medical industries, has achieved a significant share of the impressive Philippine pharma and medical device market, valued at approximately US$5.05 billion1,2. Even as a relatively young player in the industry, this achievement solidifies their position as strong leaders in healthcare. The leaders innovative approaches and strategic insights have set the organization on a path for long-term growth and prosperity.
DELEX plans to develop more product ranges, secure more distribution rights, expand its worldwide distribution networks, and invest in manufacturers of healthcare products and providers of healthcare services. The expansion plans are multi-faceted, involving a range of strategic activities designed to both capture new markets and improve its current services. Key components of the expansion strategy include:
DELEX plans to continue developing and obtaining patents for more medical and critical care items. This will be able to broaden its product line to include a range of products for critical care and the treatment of major illnesses such as cardiovascular disease, diabetes, cancer, COVID-related diseases, immunity, and anti-aging, including stem cells and probiotics. Currently, it has twenty-five (25) company-owned brands, 20 (twenty) of which are granted trademarks by the Intellectual Property Office of the Philippines (IPOPH)3. Note that Delex has two (2) subsidiary companies namely, JMN Brothers Pharma Limited Inc. and MD Pharma
By designating knowledgeable distributors, establishing strategic alliances with healthcare professionals and hospital institutions, and utilizing its own sales force, DELEX intends to establish additional distribution channels throughout the world. This will facilitate faster product sales and market expansion. Additional strategic partnerships with distributors of healthcare products with wide existing distribution channels in each region or country globally will be utilized for more distribution.
DELEX intends to partner with manufacturers and healthcare providers like hospitals, clinics, diagnostic centers, and Health Maintenance Organizations (HMOs). These partnerships will lessen the cost of products, offer competitive prices, expand markets, and let the company interact first-hand with the market for valuable data gathering which can be used for further improvement.
Delex Pharmacy is DELEXs way of offering a wide variety of affordable, branded, and generic over-the-counter and prescription medicines to their market, with the addition of other health and wellness product offerings. To continue the service from offline to online, Delex Pharmacy plans to offer online services and purchases through its 24/7 express delivery and ordering service, as well as grow its pharmacy across the country and region with more branches.
The global healthcare industry promises rapid but consistent growth, and DELEX stays on top in making sure that these trends are accounted for in its innovative solutions and patient-centric approach. Driven by a clear vision for growth and leadership, DELEXs expansion plans assure investors, shareholders, and partners a great opportunity to participate in the growth story of a dynamic and forward-thinking company. With a strong foundation of partnership with BNCM, proven leadership, and promising product lines, DELEX is well-positioned to deliver value to its partners in the long term.
BNCM is an Asset Management Company that secures its assets by investing in companies with strong growth potentials, robust revenues, significant profits, proven track records, and promising business models with highly experienced management teams that will exceptionally qualify for quotation and or listing on the NASDAQ Market within the next 2 to 3 years. The growth of these companies will directly provide more employment opportunities to the communities, improve the country’s economy, and bring greater social change to humanity.
For more information, visit: https://www.bncm.net/
DELEX is a Delaware-registered company, and a holding company of DLX Holdings, Inc. (DLX). DLX is a Philippine-based parent company that holds a 60% controlling interest in Delex Pharma International, Inc. an ISO 9001-2015 Certified company while also holding a controlling interest in JMN Brother’s Pharma Limited, Inc. DLX and its subsidiaries are involved in the development and distribution of pharmaceutical and healthcare products in the Philippines.
For more information, visit: https://delexhealth.com/
